Celcuity (CELC) Non-Current Debt (2021 - 2025)
Celcuity's (CELC) quarterly Non-Current Debt came in at $126.5 million in Q4 2025, up 29.47% YoY from $97.7 million in Q4 2024, and up 1.09% on a QoQ basis from $125.2 million in Q3 2025.
Celcuity (CELC) Non-Current Debt (2021 - 2025) Analysis & Trends
Celcuity (CELC) has 5 years of Non-Current Debt data on file, last reported at $126.5 million in Q4 2025.
- Quarterly Non-Current Debt rose 29.47% year-over-year to $126.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $126.5 million (up 29.47% YoY) and the FY2025 annual result came in at $126.5 million, up 29.47% from the prior year.
- Non-Current Debt grew to $126.5 million in Q4 2025, from $125.2 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $126.5 million in Q4 2025 to a low of $14.2 million in Q2 2021.
- A 5-year average of $55.1 million and a median of $36.5 million in 2023 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2024 — Non-Current Debt surged 167.31% — and 2025, when it advanced 3.2%.
- Tracing CELC's Non-Current Debt over 5 years: stood at $14.6 million in 2021, then jumped by 139.19% to $35.0 million in 2022, then increased by 5.87% to $37.0 million in 2023, then soared by 163.87% to $97.7 million in 2024, then increased by 29.47% to $126.5 million in 2025.
- The last three Non-Current Debt figures came in at $126.5 million (Q4 2025), $125.2 million (Q3 2025), and $99.3 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Celcuity | 4.50 Bn | 4.50 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 126.53 Mn |
| Sep 30, 2025 | 125.17 Mn |
| Jun 30, 2025 | 99.28 Mn |
| Mar 31, 2025 | 98.53 Mn |
| Dec 31, 2024 | 97.73 Mn |
| Sep 30, 2024 | 96.92 Mn |
| Jun 30, 2024 | 96.19 Mn |
| Mar 31, 2024 | 37.57 Mn |
| Dec 31, 2023 | 37.04 Mn |
| Sep 30, 2023 | 36.51 Mn |
| Jun 30, 2023 | 35.99 Mn |
| Mar 31, 2023 | 35.48 Mn |
| Dec 31, 2022 | 34.98 Mn |
| Sep 30, 2022 | 15.01 Mn |
| Jun 30, 2022 | 15.01 Mn |
| Mar 31, 2022 | 14.82 Mn |
| Dec 31, 2021 | 14.63 Mn |
| Sep 30, 2021 | 14.43 Mn |
| Jun 30, 2021 | 14.23 Mn |